Rtw Biotech Regulatory News (RTW)

LEI: 549300Q7EXQQH6KF7Z84

01 May 2024

RTW Biotech Opportunities Ltd (the "Company")

Total Voting Rights

In accordance with the FCA's Disclosure Guidance and Transparency Rule 5.6.1R the Company would like to notify the market of the following:

At the close of business on 30 April 2024, the Company had 394,290,303 Ordinary shares in issue, of which 9,603,791 were held in Treasury. Therefore, the total number of voting rights in the Company was 384,686,512**.

The above figure of 384,686,512 may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

**As per the "Completion of Acquisition" announcement published on 13 February 2024, the denominator used for the NAV per share calculation will exclude the 48,322,863 New RTW Bio Shares issued to RTW Biotech Opportunities Operating Ltd in respect of its shareholding in Arix held by the Company.

For Further Information:

About RTW Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd for more information.